NASDAQ:CASI - CASI Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 622.89 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.42
▲ +0.04 (10.67%)

This chart shows the closing price for CASI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CASI Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CASI

Analyst Price Target is $3.00
▲ +622.89% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CASI Pharmaceuticals in the last 3 months. The average price target is $3.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 622.89% upside from the last price of $0.42.

This chart shows the closing price for CASI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in CASI Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022HC WainwrightLower Price Target$4.00 ➝ $3.00Low
11/15/2021HC WainwrightReiterated RatingBuy$4.00Medium
5/17/2021BTIG ResearchInitiated CoverageBuy$4.00High
5/14/2021HC WainwrightBoost Price TargetBuy$3.50 ➝ $4.00Low
4/26/2021MizuhoInitiated CoverageBuy$3.80High
11/10/2020OppenheimerReiterated RatingBuy$5.00High
10/23/2020OppenheimerInitiated CoverageOutperform$5.00High
3/24/2020HC WainwrightReiterated RatingBuy$7.00 ➝ $3.50Medium
5/16/2019HC WainwrightReiterated RatingBuy$7.00Low
11/21/2018HC WainwrightSet Price TargetBuy$7.00High
4/4/2018HC WainwrightReiterated RatingBuy$7.00High
1/29/2018HC WainwrightReiterated RatingBuy$4.50High
1/16/2018HC WainwrightReiterated RatingBuy$5.00High
11/14/2017Maxim GroupSet Price TargetBuy$4.00N/A
9/8/2017HC WainwrightReiterated RatingBuy$2.00Medium
9/8/2017Maxim GroupReiterated RatingBuy$4.00High
8/14/2017Maxim GroupSet Price TargetBuy$4.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/27/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
1/25/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/25/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
CASI Pharmaceuticals logo
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Read More

Today's Range

Now: $0.42
Low: $0.38
High: $0.44

50 Day Range

MA: $0.59
Low: $0.31
High: $0.93

52 Week Range

Now: $0.42
Low: $0.31
High: $1.78

Volume

369,021 shs

Average Volume

512,406 shs

Market Capitalization

$56.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of CASI Pharmaceuticals?

The following equities research analysts have issued research reports on CASI Pharmaceuticals in the last year: HC Wainwright, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for CASI.

What is the current price target for CASI Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for CASI Pharmaceuticals in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 622.9%.
View the latest price targets for CASI.

What is the current consensus analyst rating for CASI Pharmaceuticals?

CASI Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CASI will outperform the market and that investors should add to their positions of CASI Pharmaceuticals.
View the latest ratings for CASI.

How do I contact CASI Pharmaceuticals' investor relations team?

CASI Pharmaceuticals' physical mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 864-2600 and its investor relations email address is [email protected] The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com. Learn More about contacing CASI Pharmaceuticals investor relations.